This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions \[smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS)\], Hodgkin lymphoma (HL), diffuse large B cell lymphoma (DLBCL), Follicular lymphoma (FL), Marginal Zone lymphomas (MZL), acute myeloid leukemia (AML)\*, myelodysplastic syndrome (MDS), subjects at risk and control subjects with no malignant disease.
\*Patients with a diagnosis of acute promyelocytic leukemia (APL) are not included
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male and female subjects ≥18 years of age
✓. Ability to understand and willingness to sign a written informed consent document.
✓. First-degree relatives; AND /OR
✓. Elderly subjects ≥ 65 years of age.
Exclusion criteria
✕. Patients/subjects with current co-diagnosis of another type of cancer;
✕. Patients/subjects with a known active or prior cancer (other than defined as study population), occurring within the last 2 years (even if considered to be in complete remission). Patients/subjects with non- melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection;
✕. Patients with a diagnosis of acute promyelocytic leukemia (APL)
✕. Patients/subjects with active inflammatory autoimmune disease that requires treatment with immunosuppressive/ immunomodulation agents;
✕. Patients/subjects with known human immunodeficiency virus (HIV) positive;
What they're measuring
1
Biomarker discovery
Timeframe: 36 month
2
Validation of Hemachip
Timeframe: 36 month
3
Early detection for hematological malignancies
Timeframe: 36 month
4
population screening for hematological malignancies